DocGo Inc.

DCGO

Nasdaq; healthcare; SIC 8000, Services-Health Services; CIK 0001822359

B

second fifth of 370 graded peers in healthcare

rank 106 of 370; percentile 28.5; sampling error 2.5 points; lower is stronger

A B C D E

B, the elk



Scoreboard


Profitability	A percentile 6.7
Solvency	C/D percentile 59.1
Growth and financing	C/D percentile 57.8
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $217.1M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	late filer; fortress balance sheet not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Mar 16, 2026 217 days before the rescan; latest periodic filing 10-Q received Aug 17, 2026
Last close	$0.27 2026-10-16; market equity $26.8M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 16, 2026

DocGo is leading the proactive healthcare revolution. We are democratizing access with our innovative care delivery platform that includes mobile health services, virtual care management and ambulance services. Our goal is to deliver healthcare at any address and help reshape the traditional healthcare system, driven by our mission to bring high quality, highly accessible care to all. DocGo's proprietary technology platform, dedicated network of certified health professionals, including virtual care clinicians, and robust fleet of medical response vehicles provide services in all 50 states and the United Kingdom.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 6.7						
Gross profitability	not computable	32.3%				
latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Accruals ratio	(64.5%)	(6.6%)	6.7	812	2025-12-31	
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 1						
Solvency, sleeve percentile 59.1						
Twelve-month failure probability	not computable	0.07%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(4.05)	(0.30)	50.7	757	2025-12-31	
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	2.26x	2.96x	67.6	840	2025-12-31	
Growth and financing, sleeve percentile 57.8						
Revenue growth, three-year compound	(9.9%)	10.1%	85.2	414	2025-12-31	
Free cash flow growth, three-year compound	5.2%	10.9%	60.0	96	2025-12-31	
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	(18.0%)	2.1%	80.4	705	2025-12-31	
Net share issuance, one year	(3.2%)	2.5%	5.7	634	2026-03-12	


Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Fortress balance sheet	cash minus debt is 50,783,074 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
101	Lineage Cell Therapeutics, Inc. (LCTX)	27.1	B	
102	Alphatec Holdings, Inc. (ATEC)	27.4	B	
103	Zoetis Inc. (ZTS)	27.6	B	
104	Agape ATP Corp. (ATPC)	27.9	B	late filer
105	Myriad Genetics Inc. (MYGN)	28.2	B	fortress balance sheet
106	DocGo Inc. (DCGO)	28.5	B	late filer, fortress balance sheet
107	Agios Pharmaceuticals, Inc. (AGIO)	28.7	B	short runway
108	Healthcare Services Group Inc. (HCSG)	29.0	B	
109	Cytokinetics Inc. (CYTK)	29.3	B	short runway
110	Staar Surgical Co. (STAA)	29.5	B	
111	Steris plc (STE)	29.8	B	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(72.0%)	8.0%	6
Distance from 52-week high	(81.8%)	(33.0%)	8
EBIT to enterprise value	(9,712.4%)	(1.7%)	0
Free cash flow yield	111.3%	(1.0%)	100
Book value to price	4.43	0.28	99
Sales to price	12.00	0.31	99
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(1.48)	(0.13)	6

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$25.2M
Operating cash flow, four quarters	-$22.7M
Months of runway	13.3
Days since last periodic filing	63 (10-Q received Aug 17, 2026)
Median daily dollar volume, 63 sessions	$229,234

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	$440.5M	2022-12-31	2025-02-27	10-K	25-000018
2	cost of revenue	us-gaap:CostOfRevenue	$523.9M	2022-12-31	2023-03-14	10-K	23-019936
3	assets	us-gaap:Assets	$393.3M	2022-12-31	2025-02-27	10-K	25-000018
4	operating income	us-gaap:OperatingIncomeLoss	-$178.0M	2025-12-31	2026-03-16	10-K	26-018214
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$187.5M	2025-12-31	2026-03-16	10-K	26-018214
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$8.9M	2025-12-31	2026-03-16	10-K	26-018214
7	total debt	us-gaap:LongTermDebt	$235,583	2025-12-31	2026-03-16	10-K	26-018214
8	book equity	us-gaap:StockholdersEquity	$144.0M	2025-12-31	2026-03-16	10-K	26-018214
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$51.0M	2025-12-31	2026-03-16	10-K	26-018214
10	total debt	us-gaap:LongTermDebt	$17,730	2024-12-31	2025-02-27	10-K	25-000018
11	book equity	us-gaap:StockholdersEquity	$320.9M	2024-12-31	2026-03-16	10-K	26-018214
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$89.2M	2024-12-31	2026-03-16	10-K	26-018214
13	net income	us-gaap:NetIncomeLoss	-$182.4M	2025-12-31	2026-03-16	10-K	26-018214
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$34.5M	2025-12-31	2026-03-16	10-K	26-018214
15	assets	us-gaap:Assets	$217.1M	2025-12-31	2026-03-16	10-K	26-018214
16	assets	us-gaap:Assets	$455.6M	2024-12-31	2026-03-16	10-K	26-018214
17	current assets	us-gaap:AssetsCurrent	$152.4M	2025-12-31	2026-03-16	10-K	26-018214
18	current liabilities	us-gaap:LiabilitiesCurrent	$67.5M	2025-12-31	2026-03-16	10-K	26-018214

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$183.8M	2025-12-31	2026-03-16	10-K	26-018214
20	liabilities	us-gaap:Liabilities	$91.2M	2025-12-31	2026-03-16	10-K	26-018214
21	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$15.7M	2025-12-31	2026-03-16	10-K	26-018214
22	revenue	us-gaap:Revenues	$322.2M	2025-12-31	2026-03-16	10-K	26-018214
23	revenue	us-gaap:Revenues	$616.6M	2024-12-31	2026-03-16	10-K	26-018214
24	revenue	us-gaap:Revenues	$624.3M	2023-12-31	2026-03-16	10-K	26-018214
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4.5M	2025-12-31	2026-03-16	10-K	26-018214
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$70.1M	2024-12-31	2026-03-16	10-K	26-018214
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.6M	2024-12-31	2026-03-16	10-K	26-018214
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$64.5M	2023-12-31	2026-03-16	10-K	26-018214
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$7.3M	2023-12-31	2026-03-16	10-K	26-018214
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$28.9M	2022-12-31	2025-02-27	10-K	25-000018
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.2M	2022-12-31	2025-02-27	10-K	25-000018
32	current assets	us-gaap:AssetsCurrent	$304.5M	2024-12-31	2026-03-16	10-K	26-018214
33	current liabilities	us-gaap:LiabilitiesCurrent	$121.8M	2024-12-31	2026-03-16	10-K	26-018214
34	assets	us-gaap:Assets	$490.5M	2023-12-31	2026-03-16	10-K	26-018214
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	98,750,251	2026-03-12	2026-03-16	10-K	26-018214
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	101,982,549	2025-02-25	2025-02-27	10-K	25-000018

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.